血管内皮生长因子A信号促进雌性骨癌大鼠脊髓中枢敏化与疼痛行为
该研究在雌性大鼠乳腺癌骨转移疼痛模型中,探讨血管内皮生长因子A(VEGF-A)及其受体VEGFR2在骨癌痛脊髓中枢敏化中的作用。结果显示肿瘤大鼠脊髓VEGF-A/VEGFR2表达上调,脊髓阻断VEGF-A或VEGFR2可显著减轻机械性痛敏、热痛敏、自发痛及步态异常,其机制涉及神经元PKC和微胶质细胞Src家族激酶通路激活。
要点
- 脊髓VEGF-A/VEGFR2信号参与骨癌痛中枢敏化。
- 脊髓阻断VEGF-A或VEGFR2可减轻骨癌痛行为。
- 机制涉及PKC介导的NMDA受体激活和Src激酶促炎因子产生。
核心结论
- VEGF-A/VEGFR2通过激活脊髓神经元PKC和微胶质细胞Src家族激酶通路参与中枢敏化和骨癌痛。
研究设计与样本
- 在雌性大鼠乳腺癌骨转移疼痛模型上,采用行为学、分子生物学和电生理方法检测脊髓VEGF-A/VEGFR2信号的作用。
主要发现
- 肿瘤大鼠脊髓VEGF-A和VEGFR2的mRNA及蛋白表达上调。
- 脊髓阻断VEGF-A或VEGFR2显著减轻肿瘤诱导的机械性痛敏(VEGF-A组7.6±2.6 g vs 5.3±3.3 g;VEGFR2组7.8±3.0 g vs 5.2±3.4 g;n=6;P<0.0001)和热痛敏(VEGF-A组9.0±2.4 s vs 7.4±2.7 s;VEGFR2组9.3±2.5 s vs 7.5±3.1 s;n=6;P<0.0001),并减轻自发痛和步态异常。
- 外源性VEGF-A以VEGFR2依赖方式增强兴奋性突触传递,在正常大鼠脊髓注射外源性VEGF-A足以通过VEGFR2介导的PKC和Src家族激酶激活引起痛敏。
- 脊髓阻断VEGF-A/VEGFR2通路抑制PKC介导的NMDA受体激活和Src家族激酶介导的促炎细胞因子产生。
临床怎么用
- 脊髓VEGF-A/VEGFR2信号通路可能是骨癌痛治疗的潜在靶点。
局限性
- 研究仅在雌性大鼠骨癌痛模型中进行,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer pain is a pervasive clinical symptom impairing life quality. Vascular endothelial growth factor A has been well studied in tumor angiogenesis and is recognized as a therapeutic target for anti-cancer treatment. This study tested the hypothesis that vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 contribute to bone cancer pain regulation associated with spinal central sensitization. METHODS: This study was performed on female rats using a metastatic breast cancer bone pain model. Nociceptive behaviors were evaluated by mechanical allodynia, thermal hyperalgesia, spontaneous pain, and CatWalk gait analysis. Expression levels were measured by real-time quantitative polymerase chain reaction, western blot, and immunofluorescence analysis. Excitatory synaptic transmission was detected by whole-cell patch-clamp recordings. The primary outcome was the effect of pharmacologic intervention of spinal vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-signaling on bone cancer pain behaviors. RESULTS: The mRNA and protein expression of vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 were upregulated in tumor-bearing rats. Spinal blocking vascular endothelial growth factor A or vascular endothelial growth factor receptor 2 significantly attenuated tumor-induced mechanical allodynia (mean ± SD: vascular endothelial growth factor A, 7.6 ± 2.6 g vs. 5.3 ± 3.3 g; vascular endothelial growth factor receptor 2, 7.8 ± 3.0 g vs. 5.2 ± 3.4 g; n = 6; P < 0.0001) and thermal hyperalgesia (mean ± SD: vascular endothelial growth factor A, 9.0 ± 2.4 s vs. 7.4 ± 2.7 s; vascular endothelial growth factor receptor 2, 9.3 ± 2.5 s vs. 7.5 ± 3.1 s; n = 6; P < 0.0001), as well as spontaneous pain and abnormal gaits. Exogenous vascular endothelial growth factor A enhanced excitatory synaptic transmission in a vascular endothelial growth factor receptor 2-dependent manner, and spinal injection of exogenous vascular endothelial growth factor A was sufficient to cause pain hypersensitivity via vascular endothelial growth factor receptor 2-mediated activation of protein kinase C and Src family kinase in naïve rats. Moreover, spinal blocking vascular endothelial growth factor A/vascular endothelial growth factor receptor 2 pathways suppressed protein kinase C-mediated N-methyl-D-aspartate receptor activation and Src family kinase-mediated proinflammatory cytokine production. CONCLUSIONS: Vascular endothelial growth factor A/vascular endothelial growth factor receptor 2 contributes to central sensitization and bone cancer pain via activation of neuronal protein kinase C and microglial Src family kinase pathways in the spinal cord.
引用
- Hu XM, Yang W, Du LX, et al. Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer. Anesthesiology. 2019. PMID: 31567367. doi:10.1097/ALN.0000000000002916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。